AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 26092818 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 719
Study 23750464 — intervention group
Group type: EXPERIMENTAL
Intervention: In-person brief motivational enhancement intervention
Number of subjects: 212
Study 23750464 — intervention group
Group type: COMPARATOR
Intervention: Assessment control group
Number of subjects: 212
Study 21276316 — intervention group
Group type: EXPERIMENTAL
Intervention: TBA Care secretion detector
Number of subjects: 72
Study 21276316 — intervention group
Group type: COMPARATOR
Intervention: Standard indications for suctioning (control group)
Number of subjects: 72
Study 19775455 — intervention group
Group type: EXPERIMENTAL
Intervention: Outreach motivational interviewing (MI)
Number of subjects: 302
Study 19775455 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 302
Study 16675379 — intervention group
Group type: EXPERIMENTAL
Intervention: Teen Club plus PALS
Number of subjects: 16
Study 16675379 — intervention group
Group type: COMPARATOR
Intervention: Teen Club
Number of subjects: 16
Study 15093800 — intervention group
Group type: EXPERIMENTAL
Intervention: Youth-friendly intervention program providing awareness, counseling, and services related to sexuality and reproduction.
Number of subjects: 2227
Study 15093800 — intervention group
Group type: COMPARATOR
Intervention: Control site with routine program activities only.
Number of subjects: 2227
Study 15093800 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group participants at onset of sexual intercourse.
Number of subjects: 2227
Study 11252074 — intervention group
Group type: EXPERIMENTAL
Intervention: Active nasal dilator strip
Number of subjects: 14
Study 11252074 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 9285305 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 alpha-reductase inhibitor (finasteride 5 mg/day)
Number of subjects: 123
Study 9285305 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 123
Study 7687111 — intervention group
Group type: EXPERIMENTAL
Intervention: PRP-OMPC vaccine
Number of subjects: 124
Study 3828185 — intervention group
Group type: EXPERIMENTAL
Intervention: Extradural phenoperidine 2 mg
Number of subjects: 0
Study 3828185 — intervention group
Group type: EXPERIMENTAL
Intervention: Extradural diamorphine 5 mg
Number of subjects: 0
Study 3828185 — intervention group
Group type: COMPARATOR
Intervention: i.m. diamorphine 5 mg
Number of subjects: 0
Study 3828185 — intervention group
Group type: EXPERIMENTAL
Intervention: Extradural groups (phenoperidine and diamorphine)
Number of subjects: 0
Study 31725196 — intervention group
Group type: EXPERIMENTAL
Intervention: Palonosetron plus aprepitant
Number of subjects: 130
Study 31725196 — intervention group
Group type: COMPARATOR
Intervention: Palonosetron alone
Number of subjects: 130
Study 31006399 — intervention group
Group type: EXPERIMENTAL
Intervention: POCUS group
Number of subjects: 201
Study 31006399 — intervention group
Group type: COMPARATOR
Intervention: Feeding group (standard procedure)
Number of subjects: 201
Study 29185403 — intervention group
Group type: EXPERIMENTAL
Intervention: Femtosecond laser-assisted cataract surgery (FLACS)
Number of subjects: 50
Study 29185403 — intervention group
Group type: COMPARATOR
Intervention: Conventional phacoemulsification
Number of subjects: 50
Study 26236130 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment group (DFDBA and barrier membrane)
Number of subjects: 24
Study 26236130 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment + doxycycline group (DFDBA and barrier membrane with local doxycycline)
Number of subjects: 24
Study 26236130 — intervention group
Group type: COMPARATOR
Intervention: Control group (DFDBA and barrier membrane without doxycycline)
Number of subjects: 24
Study 26236130 — intervention group
Group type: COMPARATOR
Intervention: Doxycycline group (DFDBA and barrier membrane with doxycycline)
Number of subjects: 24
Study 23332533 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-monitoring (SM) intervention, daily dietary logs for 6 weeks
Number of subjects: 40
Study 23332533 — intervention group
Group type: COMPARATOR
Intervention: Attention-control (AC) condition
Number of subjects: 40
Study 21700946 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational interviewing (MI) - 4 individual, weekly sessions
Number of subjects: 411
Study 21700946 — intervention group
Group type: COMPARATOR
Intervention: Usual stroke care (Control)
Number of subjects: 411
Study 19625862 — intervention group
Group type: EXPERIMENTAL
Intervention: Scheduled telephone intervention (up to 7 sessions over 9 months)
Number of subjects: 171
Study 19625862 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 171
Study 19625862 — intervention group
Group type: EXPERIMENTAL
Intervention: Scheduled telephone intervention (for those more depressed at baseline)
Number of subjects: 171
Study 16703253 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser acupuncture (5 mW HeNe laser on 22 acupuncture points for 15 s each) plus cervical collar and a combination of paracetamol and chlormezanone
Number of subjects: 45
Study 16703253 — intervention group
Group type: COMPARATOR
Intervention: Placebo laser treatment plus cervical collar and a combination of paracetamol and chlormezanone
Number of subjects: 45
Study 15319718 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxandrolone (10 mg po BID)
Number of subjects: 41
Study 15319718 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study 15319718 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxandrolone
Number of subjects: 41
Study 11680441 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 25
Study 11680441 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 25
Study 9648764 — intervention group
Group type: EXPERIMENTAL
Intervention: 14-gauge biopsy needle
Number of subjects: 64
Study 9648764 — intervention group
Group type: COMPARATOR
Intervention: 16-gauge biopsy needle
Number of subjects: 64
Study 9648764 — intervention group
Group type: COMPARATOR
Intervention: 18-gauge biopsy needle
Number of subjects: 64
Study 7853450 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic training
Number of subjects: 48
Study 7853450 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength training
Number of subjects: 48
Study 7853450 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined aerobic and strength training
Number of subjects: 48
Study 7853450 — intervention group
Group type: COMPARATOR
Intervention: No training (control)
Number of subjects: 48
Study 7853450 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower limb pain tolerance
Number of subjects: 48
Study 2524203 — intervention group
Group type: EXPERIMENTAL
Intervention: Thyroid hormone supplementation
Number of subjects: 44
Study 2524203 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 73912 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyglycolic acid (P.G.A.) suture material
Number of subjects: 1000
Study 73912 — intervention group
Group type: COMPARATOR
Intervention: Silk suture material
Number of subjects: 1000
Study 29362258 — intervention group
Group type: EXPERIMENTAL
Intervention: FreeO2 technology
Number of subjects: 47
Study 29362258 — intervention group
Group type: COMPARATOR
Intervention: Manual oxygen titration
Number of subjects: 47
Study 30261837 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.75% ropivacaine sprayed on the tracheal mucosa, epiglottis, tongue base, and glottis
Number of subjects: 54
Study 30261837 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.75% ropivacaine
Number of subjects: 54
Study 30261837 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 54
Study 28703316 — intervention group
Group type: EXPERIMENTAL
Intervention: Ertugliflozin 15 mg
Number of subjects: 36
Study 28703316 — intervention group
Group type: COMPARATOR
Intervention: Control group (normal renal function)
Number of subjects: 36
Study 26569658 — intervention group
Group type: EXPERIMENTAL
Intervention: Sofosbuvir and Velpatasvir for 12 weeks
Number of subjects: 267
Study 26569658 — intervention group
Group type: EXPERIMENTAL
Intervention: Sofosbuvir and Velpatasvir plus Ribavirin for 12 weeks
Number of subjects: 267
Study 26569658 — intervention group
Group type: EXPERIMENTAL
Intervention: Sofosbuvir and Velpatasvir for 24 weeks
Number of subjects: 267
Study 26569658 — intervention group
Group type: COMPARATOR
Intervention: Ribavirin (in combination with Sofosbuvir and Velpatasvir)
Number of subjects: 267
Study 26569658 — intervention group
Group type: COMPARATOR
Intervention: All treatment groups
Number of subjects: 267
Study 23593314 — intervention group
Group type: EXPERIMENTAL
Intervention: Tipranavir-Ritonavir based regimen
Number of subjects: 0
Study 23593314 — intervention group
Group type: EXPERIMENTAL
Intervention: Darunavir-Ritonavir based regimen
Number of subjects: 0
Study 23593314 — intervention group
Group type: EXPERIMENTAL
Intervention: Tipranavir-Ritonavir or Darunavir-Ritonavir based regimen
Number of subjects: 0
Study 23593314 — intervention group
Group type: COMPARATOR
Intervention: Investigator selected boosted comparator HIV-1 protease inhibitors (CPI-Ritonavir)
Number of subjects: 0
Study 21037482 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored cardiac rehabilitation program with motivational interviewing
Number of subjects: 225
Study 21037482 — intervention group
Group type: COMPARATOR
Intervention: Traditional cardiac rehabilitation program
Number of subjects: 225
Study 18280961 — intervention group
Group type: EXPERIMENTAL
Intervention: Mini-flap procedure
Number of subjects: 129
Study 18280961 — intervention group
Group type: COMPARATOR
Intervention: Flap procedure
Number of subjects: 129
Study 16920858 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron supplementation (30 mg daily for 6 months)
Number of subjects: 517
Study 16920858 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc supplementation (30 mg daily for 6 months)
Number of subjects: 517
Study 16920858 — intervention group
Group type: EXPERIMENTAL
Intervention: Both iron and zinc supplementation
Number of subjects: 517
Study 16920858 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 517
Study 12943174 — intervention group
Group type: EXPERIMENTAL
Intervention: Kyuki‐chouketsu‐in at a dose of 6.0 g/day (Group K)
Number of subjects: 171
Study 12943174 — intervention group
Group type: COMPARATOR
Intervention: Ergometrine (methylergometrine maleate) at a dose of 0.375 mg/day (Group E)
Number of subjects: 171
Study 12943174 — intervention group
Group type: EXPERIMENTAL
Intervention: Kyuki‐chouketsu‐in (Group K)
Number of subjects: 171
Study 12943174 — intervention group
Group type: COMPARATOR
Intervention: Ergometrine (Group E)
Number of subjects: 171
Study 10848853 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprotinin (2 x 10^6 units bolus, followed by 0.5 x 10^6 units infusion every 30 min)
Number of subjects: 77
Study 10848853 — intervention group
Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 77
Study 9332684 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose MTX
Number of subjects: 127
Study 9332684 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-dose MTX
Number of subjects: 127
Study 9332684 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy with MTX and CDP
Number of subjects: 127
Study 9332684 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment
Number of subjects: 127
Study 9332684 — intervention group
Group type: EXPERIMENTAL
Intervention: Relapse-free interval longer than 24 months
Number of subjects: 127
Study 9332684 — intervention group
Group type: EXPERIMENTAL
Intervention: Relapse-free interval shorter than 24 months
Number of subjects: 127
Study 9332684 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients not surgically treated
Number of subjects: 127
Study 9332684 — intervention group
Group type: EXPERIMENTAL
Intervention: Good histologic response
Number of subjects: 127
Study 9332684 — intervention group
Group type: EXPERIMENTAL
Intervention: LDH baseline value within normal range
Number of subjects: 127
Study 12959279 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of enalapril and doxazosin
Number of subjects: 12
Study 12959279 — intervention group
Group type: COMPARATOR
Intervention: Enalapril
Number of subjects: 12
Study 12959279 — intervention group
Group type: COMPARATOR
Intervention: Doxazosin
Number of subjects: 12
Study 2433701 — intervention group
Group type: EXPERIMENTAL
Intervention: Griseofulvin, 125 mg four times daily
Number of subjects: 57
Study 2433701 — intervention group
Group type: EXPERIMENTAL
Intervention: Methisoprinol, 1 g four times daily
Number of subjects: 57
Study 2433701 — intervention group
Group type: EXPERIMENTAL
Intervention: Griseofulvin plus methisoprinol (dosage schedules as above)
Number of subjects: 57
Study 2433701 — intervention group
Group type: COMPARATOR
Intervention: Placebo, four times daily
Number of subjects: 57
Study 30044846 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrin sealant
Number of subjects: 466
Study 30044846 — intervention group
Group type: COMPARATOR
Intervention: Standard care (no fibrin sealant)
Number of subjects: 466
Study 26271769 — intervention group
Group type: EXPERIMENTAL
Intervention: Bright Light (BL, 4420 lx) for 120 min prior to and during exercise (2HEX)
Number of subjects: 41
Study 26271769 — intervention group
Group type: COMPARATOR
Intervention: Moderate Light (ML, 230 lx) for 120 min prior to and during exercise (2HEX)
Number of subjects: 41
Study 26271769 — intervention group
Group type: EXPERIMENTAL
Intervention: Bright Light (BL, 4420 lx) for 60 min prior to and during exercise (1HEX)
Number of subjects: 41
Study 26271769 — intervention group
Group type: COMPARATOR
Intervention: Moderate Light (ML, 230 lx) for 60 min prior to and during exercise (1HEX)
Number of subjects: 41
Study 26271769 — intervention group
Group type: EXPERIMENTAL
Intervention: Bright Light (BL, 4420 lx) for 60 min prior to exercise (1H)
Number of subjects: 41
Study 26271769 — intervention group
Group type: COMPARATOR
Intervention: Moderate Light (ML, 230 lx) for 60 min prior to exercise (1H)
Number of subjects: 41
Study 24329943 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention based on health locus of control
Number of subjects: 230
Study 24329943 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 230
Study 24260184 — intervention group
Group type: EXPERIMENTAL
Intervention: Astaxanthin supplementation (20 mg/day)
Number of subjects: 32
Study 24260184 — intervention group
Group type: COMPARATOR
Intervention: Placebo supplementation
Number of subjects: 32
Study 21440994 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MI)
Number of subjects: 75
Study 19032133 — intervention group
Group type: EXPERIMENTAL
Intervention: tolterodine ER (4 mg)
Number of subjects: 617
Study 19032133 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 617
Study 16368313 — intervention group
Group type: EXPERIMENTAL
Intervention: Dalteparin
Number of subjects: 100
Study 16368313 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated Heparin (UFH)
Number of subjects: 100
Study 16368313 — intervention group
Group type: COMPARATOR
Intervention: Composite outcome (death, myocardial infarction, target vessel revascularization, or bailout glycoprotein IIb/IIIa)
Number of subjects: 100
Study 14629657 — intervention group
Group type: EXPERIMENTAL
Intervention: Conference abstracts from the Thoracic Society of Australia and New Zealand
Number of subjects: 9691
Study 10979921 — intervention group
Group type: EXPERIMENTAL
Intervention: Influenza vaccine
Number of subjects: 0
Study 8810694 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 degree flexion axial radiography (AR)
Number of subjects: 31
Study 8810694 — intervention group
Group type: COMPARATOR
Intervention: Computerized tomography (CT)
Number of subjects: 31
Study 8810694 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadriceps muscle contraction
Number of subjects: 31
Study 8810694 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 degrees AR
Number of subjects: 31
Study 1358231 — intervention group
Group type: EXPERIMENTAL
Intervention: 7 mg muscimol (GABA agonist)
Number of subjects: 10
Study 1358231 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 2951501 — intervention group
Group type: EXPERIMENTAL
Intervention: SR 270258 (2 mg/m2, subcutaneous injections, three times per week for 1 month)
Number of subjects: 16
Study 2951501 — intervention group
Group type: COMPARATOR
Intervention: Control (untreated patients)
Number of subjects: 16
Study 31004243 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet behavioral weight loss program (WT LOSS)
Number of subjects: 40
Study 31004243 — intervention group
Group type: COMPARATOR
Intervention: Internet education control (CONTROL)
Number of subjects: 40
Study 29783041 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized response technique (RRT) combined with network scale-up method (NSUM)
Number of subjects: 0
Study 29783041 — intervention group
Group type: COMPARATOR
Intervention: Network scale-up method (NSUM)
Number of subjects: 0
Study 29783041 — intervention group
Group type: COMPARATOR
Intervention: Multiplier method
Number of subjects: 0
Study 25939797 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C supplementation for 4 weeks
Number of subjects: 141
Study 25939797 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment for 4 weeks
Number of subjects: 141
Study 25552610 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholecalciferol (4000 IU/day)
Number of subjects: 0
Study 25552610 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 22034637 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyridorin 150 mg twice daily
Number of subjects: 317
Study 22034637 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyridorin 300 mg twice daily
Number of subjects: 317
Study 22034637 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 317
Study 20447477 — intervention group
Group type: EXPERIMENTAL
Intervention: Trivalent inactivated influenza vaccine (TIV)
Number of subjects: 3
Study 18484199 — intervention group
Group type: EXPERIMENTAL
Intervention: Chitosan 0.1%
Number of subjects: 140
Study 18484199 — intervention group
Group type: COMPARATOR
Intervention: Sodium hyaluronate 1.4%
Number of subjects: 140
Study 16843455 — intervention group
Group type: EXPERIMENTAL
Intervention: rosiglitazone (4 mg twice daily)
Number of subjects: 31
Study 16843455 — intervention group
Group type: EXPERIMENTAL
Intervention: metformin (1 g twice daily)
Number of subjects: 31
Study 16843455 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 31
Study 12802025 — intervention group
Group type: EXPERIMENTAL
Intervention: Involved-field radiotherapy (24 Gy to involved nodal areas, 16 to 24 Gy to extranodal sites)
Number of subjects: 421
Study 12802025 — intervention group
Group type: COMPARATOR
Intervention: No further treatment
Number of subjects: 421
Study 12802025 — intervention group
Group type: EXPERIMENTAL
Intervention: Involved-field radiotherapy (30 Gy to nodal areas, 18 to 24 Gy to extranodal sites)
Number of subjects: 421
Study 10427138 — intervention group
Group type: EXPERIMENTAL
Intervention: p53 mutation
Number of subjects: 135
Study 10427138 — intervention group
Group type: EXPERIMENTAL
Intervention: CDKN2A mutation
Number of subjects: 135
Study 10427138 — intervention group
Group type: EXPERIMENTAL
Intervention: PTEN mutation
Number of subjects: 135
Study 10427138 — intervention group
Group type: EXPERIMENTAL
Intervention: p53 genetic status
Number of subjects: 135
Study 10427138 — intervention group
Group type: EXPERIMENTAL
Intervention: CDKN2A and PTEN alterations
Number of subjects: 135
Study 7770983 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-sphere plug
Number of subjects: 40
Study 7770983 — intervention group
Group type: EXPERIMENTAL
Intervention: One-sphere plug
Number of subjects: 40
Study 7770983 — intervention group
Group type: EXPERIMENTAL
Intervention: Preference plug (either two-sphere or one-sphere)
Number of subjects: 40
Study 7770983 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-sphere device
Number of subjects: 40
Study 7770983 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall treatment
Number of subjects: 40
Study 7770983 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinary tract infections
Number of subjects: 40
Study 2272291 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic sclerotherapy (PST)
Number of subjects: 63
Study 2272291 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 63
Study 340006 — intervention group
Group type: EXPERIMENTAL
Intervention: Indoprofen 800 mg/day
Number of subjects: 36
Study 340006 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen 500 mg/day
Number of subjects: 36
Study 340006 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 31810854 — intervention group
Group type: EXPERIMENTAL
Intervention: Verum TTNS
Number of subjects: 9
Study 31810854 — intervention group
Group type: COMPARATOR
Intervention: Sham TTNS
Number of subjects: 9
Study 30779616 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated binocular stimulation mode with low temporal frequency
Number of subjects: 97
Study 30779616 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated binocular stimulation mode with high temporal frequency
Number of subjects: 97
Study 30779616 — intervention group
Group type: EXPERIMENTAL
Intervention: Contrast balance adjusted in horizontal state
Number of subjects: 97
Study 30779616 — intervention group
Group type: EXPERIMENTAL
Intervention: Contrast balance adjusted in vertical state
Number of subjects: 97
Study 26406911 — intervention group
Group type: EXPERIMENTAL
Intervention: High carbohydrate nutritional intervention (HCHO)
Number of subjects: 13
Study 26406911 — intervention group
Group type: COMPARATOR
Intervention: Moderate carbohydrate nutritional intervention (CON)
Number of subjects: 13
Study 26180251 — intervention group
Group type: EXPERIMENTAL
Intervention: Saturated fatty acids (SFAs)
Number of subjects: 33665
Study 26180251 — intervention group
Group type: EXPERIMENTAL
Intervention: Monounsaturated fatty acids (MUFAs)
Number of subjects: 33665
Study 23835717 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D‐CRT APBI (38.5 Gy in 10 fractions twice daily)
Number of subjects: 2135
Study 23835717 — intervention group
Group type: COMPARATOR
Intervention: WBI (42.5 Gy in 16 or 50 Gy in 25 daily fractions ± boost irradiation)
Number of subjects: 2135
Study 23835717 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D‐CRT APBI
Number of subjects: 2135
Study 23835717 — intervention group
Group type: COMPARATOR
Intervention: WBI
Number of subjects: 2135